163 related articles for article (PubMed ID: 37796708)
21. Correspondence on 'Safety and tolerability of nintedanib in patients with systemic sclerosis-associated interstitial lung disease: data from the SENSCIS trial'.
Bredemeier M
Ann Rheum Dis; 2022 Dec; 81(12):e250. PubMed ID: 33023963
[No Abstract] [Full Text] [Related]
22. Histopathology of pulmonary fibrotic disorders.
Lai CK; Wallace WD; Fishbein MC
Semin Respir Crit Care Med; 2006 Dec; 27(6):613-22. PubMed ID: 17195138
[TBL] [Abstract][Full Text] [Related]
23. Nintedanib: A Review in Fibrotic Interstitial Lung Diseases.
Lamb YN
Drugs; 2021 Apr; 81(5):575-586. PubMed ID: 33765296
[TBL] [Abstract][Full Text] [Related]
24. Targeted nanotherapy with everolimus reduces inflammation and fibrosis in scleroderma-related interstitial lung disease developed by PSGL-1 deficient mice.
González-Sánchez E; Muñoz-Callejas A; Gómez-Román J; San Antonio E; Marengo A; Tsapis N; Bohne-Japiassu K; González-Tajuelo R; Pereda S; García-Pérez J; Cavagna L; González-Gay MÁ; Vicente-Rabaneda EF; Meloni F; Fattal E; Castañeda S; Urzainqui A
Br J Pharmacol; 2022 Sep; 179(18):4534-4548. PubMed ID: 35726496
[TBL] [Abstract][Full Text] [Related]
25. Interstitial lung diseases associated with collagen vascular diseases: radiologic and histopathologic findings.
Kim EA; Lee KS; Johkoh T; Kim TS; Suh GY; Kwon OJ; Han J
Radiographics; 2002 Oct; 22 Spec No():S151-65. PubMed ID: 12376608
[TBL] [Abstract][Full Text] [Related]
26. CCL18 in serum, BAL fluid and alveolar macrophage culture supernatant in interstitial lung diseases.
Cai M; Bonella F; He X; Sixt SU; Sarria R; Guzman J; Costabel U
Respir Med; 2013 Sep; 107(9):1444-52. PubMed ID: 23831213
[TBL] [Abstract][Full Text] [Related]
27. Inhibitory effects of pirfenidone on fibroblast to myofibroblast transition in rheumatoid arthritis-associated interstitial lung disease via the downregulation of activating transcription factor 3 (ATF3).
Wu C; Lin H; Zhang X
Int Immunopharmacol; 2019 Sep; 74():105700. PubMed ID: 31228816
[TBL] [Abstract][Full Text] [Related]
28. Anti-fibrotic effects of pirfenidone by interference with the hedgehog signalling pathway in patients with systemic sclerosis-associated interstitial lung disease.
Xiao H; Zhang GF; Liao XP; Li XJ; Zhang J; Lin H; Chen Z; Zhang X
Int J Rheum Dis; 2018 Feb; 21(2):477-486. PubMed ID: 29316328
[TBL] [Abstract][Full Text] [Related]
29. Extracellular Heat Shock Proteins as Therapeutic Targets and Biomarkers in Fibrosing Interstitial Lung Diseases.
Tanguy J; Pommerolle L; Garrido C; Kolb M; Bonniaud P; Goirand F; Bellaye PS
Int J Mol Sci; 2021 Aug; 22(17):. PubMed ID: 34502225
[TBL] [Abstract][Full Text] [Related]
30. Pharmacological management of progressive-fibrosing interstitial lung diseases: a review of the current evidence.
Richeldi L; Varone F; Bergna M; de Andrade J; Falk J; Hallowell R; Jouneau S; Kondoh Y; Morrow L; Randerath W; Strek M; Tabaj G
Eur Respir Rev; 2018 Dec; 27(150):. PubMed ID: 30578333
[TBL] [Abstract][Full Text] [Related]
31. Pulmonary fibrosis: from pathogenesis to clinical decision-making.
Koudstaal T; Funke-Chambour M; Kreuter M; Molyneaux PL; Wijsenbeek MS
Trends Mol Med; 2023 Dec; 29(12):1076-1087. PubMed ID: 37716906
[TBL] [Abstract][Full Text] [Related]
32. Pirfenidone in patients with progressive fibrotic interstitial lung diseases other than idiopathic pulmonary fibrosis (RELIEF): a double-blind, randomised, placebo-controlled, phase 2b trial.
Behr J; Prasse A; Kreuter M; Johow J; Rabe KF; Bonella F; Bonnet R; Grohe C; Held M; Wilkens H; Hammerl P; Koschel D; Blaas S; Wirtz H; Ficker JH; Neumeister W; Schönfeld N; Claussen M; Kneidinger N; Frankenberger M; Hummler S; Kahn N; Tello S; Freise J; Welte T; Neuser P; Günther A;
Lancet Respir Med; 2021 May; 9(5):476-486. PubMed ID: 33798455
[TBL] [Abstract][Full Text] [Related]
33. Correlation of cough with disease activity and treatment with cyclophosphamide in scleroderma interstitial lung disease: findings from the Scleroderma Lung Study.
Theodore AC; Tseng CH; Li N; Elashoff RM; Tashkin DP
Chest; 2012 Sep; 142(3):614-621. PubMed ID: 22156609
[TBL] [Abstract][Full Text] [Related]
34. Integrating Genomics Into Management of Fibrotic Interstitial Lung Disease.
Adegunsoye A; Vij R; Noth I
Chest; 2019 May; 155(5):1026-1040. PubMed ID: 30660786
[TBL] [Abstract][Full Text] [Related]
35. An analysis of connective tissue disease-associated interstitial lung disease at a US Tertiary Care Center: better survival in patients with systemic sclerosis.
Su R; Bennett M; Jacobs S; Hunter T; Bailey C; Krishnan E; Rosen G; Chung L
J Rheumatol; 2011 Apr; 38(4):693-701. PubMed ID: 21285162
[TBL] [Abstract][Full Text] [Related]
36. A new therapy for systemic sclerosis-associated interstitial lung disease.
Kondoh Y
Respir Investig; 2020 Jul; 58(4):227-229. PubMed ID: 32451295
[No Abstract] [Full Text] [Related]
37. [New developments in systemic sclerosis-associated interstitial lung disease].
Humair G; Daccord C; Beigelman-Aubry C; Lazor R
Rev Med Suisse; 2020 Nov; 16(715):2218-2223. PubMed ID: 33206479
[TBL] [Abstract][Full Text] [Related]
38. Association of COVID-19 and other viral infections with interstitial lung diseases, pulmonary fibrosis, and pulmonary hypertension: A narrative review.
Atabati E; Dehghani-Samani A; Mortazavimoghaddam SG
Can J Respir Ther; 2020; 56():1-9. PubMed ID: 33274259
[TBL] [Abstract][Full Text] [Related]
39. Novel Therapeutic Approaches for Pulmonary Manifestations of Systemic Sclerosis.
Lui JK; Bosch NA; Gillmeyer KR; Reardon CC
Am J Respir Crit Care Med; 2020 Sep; 202(6):878-880. PubMed ID: 32574505
[No Abstract] [Full Text] [Related]
40. Interstitial lung disease in scleroderma.
Schoenfeld SR; Castelino FV
Rheum Dis Clin North Am; 2015 May; 41(2):237-48. PubMed ID: 25836640
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
